BACKGROUND: The extraordinary invasiveness of human glioblastoma multiforme (GBM) contributes to treatment failure and the grim prognosis of patients diagnosed with this tumor. Consequently, it is imperative to define further the cellular mechanisms that control GBM invasion and identify promising novel therapeutic targets. Melanoma differentiation associated gene-9 (MDA-9/syntenin) is a highly conserved PDZ domain-containing scaffolding protein that promotes invasion and metastasis in vitro and in vivo in human melanoma models. To determine whether MDA-9/syntenin is a relevant target in GBM, we investigated its expression in tumor samples and involvement in GBM invasion and angiogenesis. MATERIALS: We assessed MDA-9/syntenin levels in available databases, patient tumor samples, and human-derived cell lines. Through gain-of-function and loss-of-function studies, we analyzed changes in invasion, angiogenesis, and signaling in vitro. We used orthotopic xenografts with GBM6 cells to demonstrate the role of MDA-9/syntenin in GBM pathogenesis in vivo. RESULTS: MDA-9/syntenin expression in high-grade astrocytomas is significantly higher than normal tissue counterparts. Forced overexpression of MDA-9/syntenin enhanced Matrigel invasion, while knockdown inhibited invasion, migration, and anchorage-independent growth in soft agar. Moreover, overexpression of MDA-9/syntenin increased activation of c-Src, p38 mitogen-activated protein kinase, and nuclear factor kappa-B, leading to elevated expression of matrix metalloproteinase 2 and secretion of interleukin-8 with corresponding changes observed upon knockdown. GBM6 cells that stably express small hairpin RNA for MDA-9/syntenin formed smaller tumors and had a less invasive phenotype in vivo. CONCLUSIONS: Our findings indicate that MDA-9/syntenin is a novel and important mediator of invasion in GBM and a key regulator of pathogenesis, and we identify it as a potential target for anti-invasive treatment in human astrocytoma.
BACKGROUND: The extraordinary invasiveness of humanglioblastoma multiforme (GBM) contributes to treatment failure and the grim prognosis of patients diagnosed with this tumor. Consequently, it is imperative to define further the cellular mechanisms that control GBM invasion and identify promising novel therapeutic targets. Melanoma differentiation associated gene-9 (MDA-9/syntenin) is a highly conserved PDZ domain-containing scaffolding protein that promotes invasion and metastasis in vitro and in vivo in humanmelanoma models. To determine whether MDA-9/syntenin is a relevant target in GBM, we investigated its expression in tumor samples and involvement in GBM invasion and angiogenesis. MATERIALS: We assessed MDA-9/syntenin levels in available databases, patienttumor samples, and human-derived cell lines. Through gain-of-function and loss-of-function studies, we analyzed changes in invasion, angiogenesis, and signaling in vitro. We used orthotopic xenografts with GBM6 cells to demonstrate the role of MDA-9/syntenin in GBM pathogenesis in vivo. RESULTS:MDA-9/syntenin expression in high-grade astrocytomas is significantly higher than normal tissue counterparts. Forced overexpression of MDA-9/syntenin enhanced Matrigel invasion, while knockdown inhibited invasion, migration, and anchorage-independent growth in soft agar. Moreover, overexpression of MDA-9/syntenin increased activation of c-Src, p38 mitogen-activated protein kinase, and nuclear factor kappa-B, leading to elevated expression of matrix metalloproteinase 2 and secretion of interleukin-8 with corresponding changes observed upon knockdown. GBM6 cells that stably express small hairpin RNA for MDA-9/syntenin formed smaller tumors and had a less invasive phenotype in vivo. CONCLUSIONS: Our findings indicate that MDA-9/syntenin is a novel and important mediator of invasion in GBM and a key regulator of pathogenesis, and we identify it as a potential target for anti-invasive treatment in humanastrocytoma.
Authors: R Bonavia; M M Inda; S Vandenberg; S-Y Cheng; M Nagane; P Hadwiger; P Tan; D W Y Sah; W K Cavenee; F B Furnari Journal: Oncogene Date: 2011-12-05 Impact factor: 9.867
Authors: R Dash; I Dmitriev; Z-z Su; S K Bhutia; B Azab; N Vozhilla; A Yacoub; P Dent; D T Curiel; D Sarkar; P B Fisher Journal: Cancer Gene Ther Date: 2010-02-12 Impact factor: 5.987
Authors: Kan V Lu; Shaojun Zhu; Anna Cvrljevic; Tiffany T Huang; Shawn Sarkaria; David Ahkavan; Julie Dang; Eduard B Dinca; Seema B Plaisier; Isaac Oderberg; Yohan Lee; Zugen Chen; Jeremy S Caldwell; Yongmin Xie; Joseph A Loo; David Seligson; Arnab Chakravari; Francis Y Lee; Roberto Weinmann; Timothy F Cloughesy; Stanley F Nelson; Gabriele Bergers; Thomas Graeber; Frank B Furnari; C David James; Webster K Cavenee; Terrance G Johns; Paul S Mischel Journal: Cancer Res Date: 2009-08-18 Impact factor: 12.701
Authors: Santanu Dasgupta; Mitchell E Menezes; Swadesh K Das; Luni Emdad; Aleksandar Janjic; Shilpa Bhatia; Nitai D Mukhopadhyay; Chunbo Shao; Devanand Sarkar; Paul B Fisher Journal: Clin Cancer Res Date: 2013-07-19 Impact factor: 12.531
Authors: Konstantin Tsoyi; Juan C Osorio; Sarah G Chu; Isis E Fernandez; Sergio Poli De Frias; Lynette Sholl; Ye Cui; Carmen S Tellez; Jill M Siegfried; Steven A Belinsky; Mark A Perrella; Souheil El-Chemaly; Ivan O Rosas Journal: Am J Respir Cell Mol Biol Date: 2019-06 Impact factor: 6.914
Authors: Swadesh K Das; Anjan K Pradhan; Praveen Bhoopathi; Sarmistha Talukdar; Xue-Ning Shen; Devanand Sarkar; Luni Emdad; Paul B Fisher Journal: Cancer Res Date: 2018-03-23 Impact factor: 12.701
Authors: Timothy P Kegelman; Bainan Wu; Swadesh K Das; Sarmistha Talukdar; Jason M Beckta; Bin Hu; Luni Emdad; Kristoffer Valerie; Devanand Sarkar; Frank B Furnari; Webster K Cavenee; Jun Wei; Angela Purves; Surya K De; Maurizio Pellecchia; Paul B Fisher Journal: Proc Natl Acad Sci U S A Date: 2016-12-23 Impact factor: 11.205
Authors: Sarmistha Talukdar; Anjan K Pradhan; Praveen Bhoopathi; Xue-Ning Shen; Laura A August; Jolene J Windle; Devanand Sarkar; Frank B Furnari; Webster K Cavenee; Swadesh K Das; Luni Emdad; Paul B Fisher Journal: Proc Natl Acad Sci U S A Date: 2018-05-14 Impact factor: 11.205
Authors: Luni Emdad; Aleksandar Janjic; Mohammad A Alzubi; Bin Hu; Prasanna K Santhekadur; Mitchell E Menezes; Xue-Ning Shen; Swadesh K Das; Devanand Sarkar; Paul B Fisher Journal: Neuro Oncol Date: 2014-09-12 Impact factor: 12.300
Authors: Swadesh K Das; Santanu Maji; Stephen L Wechman; Praveen Bhoopathi; Anjan K Pradhan; Sarmistha Talukdar; Devanand Sarkar; Joseph Landry; Chunqing Guo; Xiang-Yang Wang; Webster K Cavenee; Luni Emdad; Paul B Fisher Journal: Pharmacol Res Date: 2020-02-13 Impact factor: 7.658
Authors: Manny D Bacolod; Swadesh K Das; Upneet K Sokhi; Steven Bradley; David A Fenstermacher; Maurizio Pellecchia; Luni Emdad; Devanand Sarkar; Paul B Fisher Journal: Adv Cancer Res Date: 2015-05-23 Impact factor: 6.242
Authors: Timothy P Kegelman; Swadesh K Das; Luni Emdad; Bin Hu; Mitchell E Menezes; Praveen Bhoopathi; Xiang-Yang Wang; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher Journal: Expert Opin Ther Targets Date: 2014-09-15 Impact factor: 6.902